204 related articles for article (PubMed ID: 11958832)
1. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.
Xu K; Xu YH; Chen JF; Schwarzschild MA
Neurosci Lett; 2002 Mar; 322(1):13-6. PubMed ID: 11958832
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.
Callier S; Morissette M; Grandbois M; Pélaprat D; Di Paolo T
Synapse; 2001 Aug; 41(2):131-8. PubMed ID: 11400179
[TBL] [Abstract][Full Text] [Related]
3. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
[TBL] [Abstract][Full Text] [Related]
4. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
Morgan WW; Nelson JF
Brain Res; 2001 Dec; 921(1-2):115-21. PubMed ID: 11720717
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
[TBL] [Abstract][Full Text] [Related]
6. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
Pope-Coleman A; Tinker JP; Schneider JS
Synapse; 2000 May; 36(2):120-8. PubMed ID: 10767059
[TBL] [Abstract][Full Text] [Related]
7. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.
Xu K; Xu YH; Chen JF; Schwarzschild MA
Neuroscience; 2010 May; 167(2):475-81. PubMed ID: 20167258
[TBL] [Abstract][Full Text] [Related]
10. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Petroske E; Meredith GE; Callen S; Totterdell S; Lau YS
Neuroscience; 2001; 106(3):589-601. PubMed ID: 11591459
[TBL] [Abstract][Full Text] [Related]
11. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Chen JF; Xu K; Petzer JP; Staal R; Xu YH; Beilstein M; Sonsalla PK; Castagnoli K; Castagnoli N; Schwarzschild MA
J Neurosci; 2001 May; 21(10):RC143. PubMed ID: 11319241
[TBL] [Abstract][Full Text] [Related]
13. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
Ikeda K; Kurokawa M; Aoyama S; Kuwana Y
J Neurochem; 2002 Jan; 80(2):262-70. PubMed ID: 11902116
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of riluzole in MPTP-treated mice.
Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
[TBL] [Abstract][Full Text] [Related]
16. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism.
Chen JF; Steyn S; Staal R; Petzer JP; Xu K; Van Der Schyf CJ; Castagnoli K; Sonsalla PK; Castagnoli N; Schwarzschild MA
J Biol Chem; 2002 Sep; 277(39):36040-4. PubMed ID: 12130655
[TBL] [Abstract][Full Text] [Related]
17. Depletion of striatal dopamine transporter does not affect psychostimulant-induced locomotor activity.
Itzhak Y; Martin JL; Ali SF; Norenberg MD
Neuroreport; 1997 Oct; 8(15):3245-9. PubMed ID: 9351651
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Teismann P; Ferger B
Synapse; 2001 Feb; 39(2):167-74. PubMed ID: 11180504
[TBL] [Abstract][Full Text] [Related]
19. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.
Anderson DW; Neavin T; Smith JA; Schneider JS
Brain Res; 2001 Jun; 905(1-2):44-53. PubMed ID: 11423078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
